GHK-Cu: What the Copper-Peptide Literature Shows

GHK-Cu has a longer research history than almost any other peptide in Wednesday’s catalog, and a stranger one. It was not designed. It was found in human blood in 1973 by a biochemist studying why liver cells from old donors behaved differently from those of young ones, and it took another seven years to establish that its activity depended on copper. Since then, work in fibroblasts, animal wounds and, more recently, gene-expression databases has built a case for GHK-Cu as a regulator of the extracellular matrix. Much of that case was assembled by the compound’s discoverer, and the human evidence has stayed small and cosmetic. This note sets out what has been shown, by whom, and in what systems.

Discovery and chemistry

In 1973, Loren Pickart and Melvin Thaler reported that a low-molecular-weight fraction of human plasma prolonged the survival of normal liver cells in culture and stimulated the growth of liver tumor cells. The active component was a tripeptide.¹ Its sequence, glycyl-L-histidyl-L-lysine, GHK, was established in 1977, and in 1980 Pickart and colleagues published in Nature that the peptide’s biological activity was linked to its avid binding of copper(II), proposing that GHK functioned by delivering copper into cells.² The histidine imidazole and the free amine of glycine form a high-affinity copper-binding site, and the resulting 1:1 complex, GHK-Cu, has a characteristic blue-violet color in concentrated solution.

GHK circulates in plasma at concentrations Pickart’s group has reported as about 200 ng/mL in young adults, falling to roughly 80 ng/mL by age 60, though these figures come from the discoverer’s own work and have not been widely replicated.³ The tripeptide also occurs as a sequence within larger proteins, notably type I collagen, from which it may be released during matrix breakdown, a possible link between tissue injury and local GHK availability. With a molecular weight of 340 Da for the free peptide and about 403 Da for the copper complex, GHK-Cu is among the smallest compounds in peptide research.

Fibroblasts and the extracellular matrix

The foundational cell-culture work came from François-Xavier Maquart’s laboratory in Reims, France, in collaboration with Pickart. In 1988 they reported that GHK-Cu stimulated collagen synthesis in cultured human fibroblasts, with activity across a wide concentration range down to the nanomolar and even picomolar level, and that the free peptide without copper was much less active.⁴ The same group went on to show increased synthesis of sulfated glycosaminoglycans, the long sugar chains that hold water in connective tissue, in the same culture system, suggesting the peptide acted on several components of the matrix rather than on collagen alone.

An independent line of fibroblast work came from Pollard and colleagues in 2005, who cultured fibroblasts from normal and irradiated human skin. Irradiated fibroblasts grow poorly and produce fewer growth factors; GHK-Cu treatment increased their proliferation and their expression of basic fibroblast growth factor and vascular endothelial growth factor, restoring them toward the behavior of normal cells.⁵ The study is small, but it is one of the few from a group with no connection to the compound’s discoverer.

GHK-Cu’s most reproducible finding is also its least glamorous: fibroblasts in a dish make more matrix when the copper peptide is present.

Animal wound models

Maquart’s group extended the fibroblast findings to living tissue in 1993 using an established rat model in which wound chambers are implanted under the skin and the connective tissue that grows into them is analyzed. GHK-Cu injected into the chambers increased the accumulation of collagen, glycosaminoglycans and total protein compared with vehicle, and the effect was seen at the site of injection and, to a lesser degree, at distant control chambers, evidence of a systemic component.⁶

Veterinary researchers have contributed several models. Canapp and colleagues applied topical GHK-Cu to ischemic open wounds and reported faster wound contraction and better-organized granulation tissue.⁷ Two Turkish groups studied open wounds in rabbits and reported improved contraction, earlier granulation and higher tissue antioxidant enzyme levels with topical GHK-Cu. Arul and colleagues incorporated a biotinylated GHK into collagen matrices and applied them to wounds in diabetic rats, finding faster contraction and re-epithelialization than with collagen alone.⁸ Across these models the direction of effect is consistent; what varies is the delivery (topical, injected, matrix-bound), the species and the outcome measures, which makes quantitative comparison difficult.

Evidence level	Systems studied	Representative findings	Independence from discoverer
In vitro	Human dermal fibroblasts4–5	Increased collagen and GAG synthesis; growth-factor expression restored in irradiated cells	Mixed; Pollard 2005 independent
In vivo, animal	Rat wound chambers; rabbit, rat and ischemic open wounds6–8	More connective tissue; faster contraction and re-epithelialization	Largely independent veterinary groups
Computational	Gene-expression databases3,9	Reversal of emphysema signature; broad gene modulation	Campbell 2012 independent; Pickart analyses not
Human	Small topical cosmetic studies10	Skin appearance measures	Mostly industry-linked; no injectable trials

The gene-expression studies

The most-cited GHK result of the past fifteen years came from an unexpected direction. Campbell and colleagues at Boston University were studying gene expression in lung tissue from patients with emphysema. They defined a signature of genes whose expression tracked the severity of lung destruction and then searched the Broad Institute’s Connectivity Map, a database of gene-expression responses to thousands of compounds, for agents that would reverse it. GHK emerged as a top candidate. In cultured human lung fibroblasts, GHK at nanomolar concentrations reversed the expression pattern and restored the cells’ capacity to contract and organize collagen, functions that are impaired in emphysema.⁹ The study did not test GHK in animals or patients, and the authors presented it as hypothesis-generating. It remains the strongest independent evidence that GHK acts on gene expression in human cells.

Pickart and colleagues subsequently mined the same database and reported that GHK altered the expression of a large fraction of human genes, over 4,000 by their count, or roughly a third of the genome, in the Connectivity Map cell lines, with increases in genes related to tissue repair and antioxidant defense and decreases in genes associated with inflammation and tissue breakdown.³ These are computational analyses of an existing dataset, not new experiments, and the biological meaning of “modulating a third of the genome” is far from clear; very many compounds produce broad expression changes in cultured cells. The analyses are best read as a catalog of hypotheses.

Human evidence

GHK-Cu has been used in cosmetic skin-care products since the 1990s, and the human literature reflects that origin. A handful of small controlled facial studies, several unpublished or reported only in cosmetic-science venues, have measured changes in skin appearance, density or wrinkle depth after topical application over weeks to months. Reviews of topical peptides in dermatology treat these results as suggestive but limited by small samples, short duration, industry sponsorship and the difficulty of separating the peptide’s effect from the vehicle’s.¹⁰ No controlled human trial of injected or systemic GHK-Cu has been published, and no GHK-Cu product is approved as a drug in any jurisdiction. Cosmetic use is regulated as a cosmetic, not as a medicine, and the concentrations and delivery involved bear no relation to research-grade lyophilized peptide.

Research considerations

For laboratory purposes, GHK-Cu is attractive precisely because its biology is matrix-focused and its activity is measurable in standard fibroblast assays. Copper stoichiometry matters: the peptide is typically supplied as the copper complex, and the ratio of copper to peptide affects both activity and stability, so a certificate of analysis for GHK-Cu should confirm identity of the tripeptide by mass spectrometry and, ideally, report copper content. The compound is hygroscopic and light-sensitive in solution. Wednesday supplies GHK-Cu as a single compound and within the GLOW blend alongside BPC-157 and TB-500; the note Peptide Blends in Research discusses why combining three matrix-active peptides complicates attribution of any observed effect, and the COA library holds per-lot results. For the biology of the other two components, see the BPC-157 and TB-500 overviews.

Frequently asked questions

What is GHK-Cu?

GHK-Cu is a complex of the tripeptide glycyl-histidyl-lysine with a copper(II) ion. The peptide occurs naturally in human plasma and was isolated in 1973. The copper complex is the form most studied, because early work showed the peptide’s activity in cell cultures depended on copper binding.

What does GHK-Cu do to collagen?

In cultured human fibroblasts, GHK-Cu increased collagen synthesis at nanomolar concentrations, along with glycosaminoglycans. In rat wound-chamber models it increased collagen accumulation in the tissue. These are cell and animal findings; controlled human data on collagen are not available.

Is GHK-Cu the same as copper peptide in skin care?

The molecule is the same, but the context is not. Cosmetic products contain GHK-Cu at low concentrations in topical formulations and are regulated as cosmetics. Research-grade GHK-Cu is a lyophilized peptide supplied for laboratory use and is not a cosmetic or an approved drug.

Does GHK-Cu really affect thousands of genes?

That figure comes from computational analyses of the Broad Institute’s Connectivity Map database by the compound’s discoverer, who reported expression changes in over 4,000 genes in cultured cell lines. An independent 2012 study did find GHK reversed a disease-linked gene signature in lung fibroblasts. Broad expression changes in culture are common and their significance is uncertain.

Has GHK-Cu been tested in humans?

Only in small studies of topical cosmetic formulations measuring skin appearance, most of them short, industry-linked and of limited size. No controlled trial of injected or systemic GHK-Cu has been published and no GHK-Cu drug is approved anywhere.

References & further reading

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85–87. PMID 4349963
2. Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715–717. doi:10.1038/288715a0 / PMID 7453802
3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108 / PMID 26236730
4. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343–346. doi:10.1016/0014-5793(88)80509-X / PMID 3169264
5. Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27–31. doi:10.1001/archfaci.7.1.27
6. Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. J Clin Invest. 1993;92(5):2368–2376. doi:10.1172/JCI116842
7. Canapp SO, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32(6):515–523. doi:10.1111/j.1532-950X.2003.00515.x / PMID 14648529
8. Arul V, Kartha R, Jayakumar R. A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sci. 2007;80(4):275–284. doi:10.1016/j.lfs.2006.09.018 / PMID 17049946
9. Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. doi:10.1186/gm367
10. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327–345. doi:10.1111/j.1468-2494.2009.00490.x / PMID 19570099